MINNEAPOLIS, Feb. 12 /PRNewswire-FirstCall/ -- Advanced Bio-Surfaces, Inc., (ABS) an orthopedic implant developer and manufacturer, announced today the successful completion of over 125 OrthoGlide Medial Knee implants in the USA.
“We’re pleased to report this many clinically successful implants. By controlling the introduction of the product we’ve been able to support our implanting orthopedic surgeons during their first cases,” said Dr. Jeff Felt, Chairman and CEO of Advanced Bio-Surfaces. “Surgeons implanting the OrthoGlide continue to share how pleased they are with the ease of implanting the device and their patient’s satisfaction with the outcome.”
Alan Markman, M.D., at TRIA Orthopedic Center in Minneapolis, MN is an experienced OrthoGlide implanter and proctors the training workshops. Dr. Markman said, “From an educator standpoint, the OrthoGlide procedure is easier to teach than the total knee replacements. From a surgeon perspective, I’m pleased that my patient’s implanted with the OrthoGlide have experienced good pain relief, minimal swelling and near full range of motion. Based on my OrthoGlide experiences, I believe that these are the standard results surgeons can typically expect with this product.”
One of the most experienced implanters of the OrthoGlide is David Esposito, M.D. practicing in Wilmington, North Carolina with the Carolina Sports Medicine and Orthopaedic Specialists. Dr. Esposito said, “The early clinical success of the OrthoGlide, as measured by patient’s pain and function scores, have been exciting and consistent within the group of patients I have implanted.” Dr. Esposito went on to say, “Surgeons are seeking to improve a patient’s quality of life through a surgical intervention while minimizing the disruption to the surrounding tissues. My personal experience is that the OrthoGlide’s minimally invasive surgical procedure does allow the patient to feel better sooner.”
About Advanced Bio-Surfaces, Inc.
ABS is a privately held company dedicated to the development of innovative joint repair products. The company’s first product, the OrthoGlide Medial Knee Implant, is intended for treatment of patients with moderate osteoarthritis of the medial compartment. The company received 510(k) clearance to market from the U.S. Food and Drug Administration (FDA) and CE mark notification from its Notified Body, in February 2006. For additional information contact Robert Siegfried at 952.912.5400.
Advanced Bio-Surfaces, Inc.
CONTACT: Robert Siegfried, VP, Finance and Administration of AdvancedBio-Surfaces, Inc., +1-952-912-5400
